CDK8/19 Inhibition Attenuates G1 Arrest Induced by BCR-ABL Antagonists and Accelerates Death of Chronic Myelogenous Leukemia Cells

Imatinib and other selective inhibitors of BCR-ABL are the mainstay of chronic myelogenous leukemia (CML) treatment, but resistance to these drugs limits their efficacy. Known resistance mechanisms include ABL mutations, activation of compensatory signaling pathways, and the induction of quiescence that protects CML cells from apoptosis. CDK8/19 Mediator kinases that regulate transcriptional reprogramming have been implicated in the development of resistance to different drugs. We have investigated the effects of CDK8/19 inhibition on CML response to BCR-ABL inhibitors. Selective CDK8/19 inhibitors Senexin B and SNX631 strongly increased the induction of apoptosis in K562 cells treated with imatinib or other BCR-ABL inhibitors. Imatinib induced G1 arrest along with upregulation of p27Kip1, but these effects were suppressed by CDK8/19 inhibition. Senexin B also prevented the induction of G1 arrest and protection from imatinib-induced apoptosis of K562 cells by inducible p27Kip1 expression, suggesting that CDK8/19 activity potentiates both the transcription and function of p27Kip1. In contrast, CDK8/18 inhibition did not have the same effect in KU812 CML cells that do not undergo G1 arrest and are hypersensitive to imatinib. Our results suggest that inhibition of CDK8/19 may be used as a new strategy to prevent quiescence-mediated resistance to BCR-ABL inhibitors.

[1]  I. Roninson,et al.  CDK8 and CDK19: positive regulators of signal-induced transcription and negative regulators of Mediator complex proteins , 2023, Nucleic acids research.

[2]  B. Győrffy,et al.  Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[3]  I. S. Pagani,et al.  Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia , 2022, Cancers.

[4]  D. Taatjes,et al.  The Mediator kinase module: an interface between cell signaling and transcription. , 2022, Trends in biochemical sciences.

[5]  Xiaochen Bo,et al.  clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.

[6]  J. Cortes,et al.  Third-line therapy for chronic myeloid leukemia: current status and future directions , 2021, Journal of Hematology & Oncology.

[7]  I. Roninson,et al.  The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs , 2021, Cells.

[8]  M. Deininger,et al.  Declaration of Bcr-Abl1 independence , 2020, Leukemia.

[9]  S. Anant,et al.  Regulatory Role of Quiescence in the Biological Function of Cancer Stem Cells , 2020, Stem Cell Reviews and Reports.

[10]  H. Kantarjian,et al.  Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring , 2020, American journal of hematology.

[11]  B. Druker,et al.  Response and Resistance to BCR-ABL1-Targeted Therapies. , 2020, Cancer cell.

[12]  M. Kazemian,et al.  CDK8 Fine-Tunes IL-6 Transcriptional Activities by Limiting STAT3 Resident Time at the Gene Loci , 2020, bioRxiv.

[13]  S. Mirarab,et al.  Sequence Analysis , 2020, Encyclopedia of Bioinformatics and Computational Biology.

[14]  G. Superti-Furga,et al.  Transcriptional Responses to IFN-γ Require Mediator Kinase-Dependent Pause Release and Mechanistically Distinct CDK8 and CDK19 Functions. , 2019, Molecular cell.

[15]  Katie L. Kathrein,et al.  Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition , 2019, Cells.

[16]  I. Roninson,et al.  Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay , 2019, Cells.

[17]  Jing Wang,et al.  WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs , 2019, Nucleic Acids Res..

[18]  A. Khamidullina,et al.  PF‑114, a novel selective inhibitor of BCR‑ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells. , 2019, International journal of oncology.

[19]  J. Eschweiler,et al.  Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling , 2019, Leukemia.

[20]  D. Taatjes,et al.  Regulatory functions of the Mediator kinases CDK8 and CDK19 , 2018, Transcription.

[21]  A. Nakamura,et al.  CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells , 2018, Oncotarget.

[22]  G. Stark,et al.  CDK8/19 Mediator kinases potentiate induction of transcription by NFκB , 2017, Proceedings of the National Academy of Sciences.

[23]  U. Olsson‐Strömberg,et al.  Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. , 2017, Blood.

[24]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[25]  B. Győrffy,et al.  Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer , 2017, Oncotarget.

[26]  Gennady Korotkevich,et al.  Fast gene set enrichment analysis , 2016, bioRxiv.

[27]  Zhijie Kang,et al.  The Philadelphia chromosome in leukemogenesis , 2016, Chinese journal of cancer.

[28]  J. Bourhis,et al.  Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation , 2016, Oncotarget.

[29]  H. Mayani,et al.  CDKIs p18INK4c and p57Kip2 are involved in quiescence of CML leukemic stem cells after treatment with TKI , 2016, Cell cycle.

[30]  Jonathan H. Esensten,et al.  Cdk8 deletion in the ApcMin murine tumour model represses EZH2 activity and accelerates tumourigenesis , 2015, The Journal of pathology.

[31]  S. Armstrong,et al.  Mediator Kinase Inhibition Further Activates Super-Enhancer Associated Genes in AML , 2015, Nature.

[32]  James M. Roberts,et al.  BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. , 2014, Blood.

[33]  Alexey A. Zeifman,et al.  PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation , 2014, Leukemia.

[34]  Michael R. Green,et al.  A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia , 2014, Science Translational Medicine.

[35]  Derek J. Wilson,et al.  Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia , 2014, Leukemia.

[36]  D. Sayed,et al.  p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy. , 2014, Leukemia research.

[37]  M. Caligiuri,et al.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. , 2013, The Journal of clinical investigation.

[38]  J. Cigudosa,et al.  MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27KIP1 , 2013, Oncogene.

[39]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[40]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[41]  L. Pfeffer,et al.  Role of BCR-ABL-Y177 mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors , 2009, Leukemia.

[42]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[43]  Ying Liu,et al.  Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis. , 2008, Cancer research.

[44]  D. Boulware,et al.  Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance , 2008, Molecular Cancer Therapeutics.

[45]  T. Holyoake,et al.  Transcriptional Analysis of Quiescent and Proliferating CD34+ Human Hemopoietic Cells from Normal and Chronic Myeloid Leukemia Sources , 2007, Stem cells.

[46]  T. Mäkelä,et al.  Cdk8 Is Essential for Preimplantation Mouse Development , 2007, Molecular and Cellular Biology.

[47]  S. Okabe,et al.  Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors , 2007, Oncogene.

[48]  S. Flamant,et al.  BCR–ABL activates STAT3 via JAK and MEK pathways in human cells , 2006, British journal of haematology.

[49]  M. Copland,et al.  Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. , 2006, Blood.

[50]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[51]  T. Holyoake,et al.  Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. , 2005, Experimental hematology.

[52]  J. Martinez-Climent,et al.  BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. , 2005, Cancer research.

[53]  M. Loda,et al.  BCR/ABL Regulates Expression of the Cyclin-dependent Kinase Inhibitor p27Kip1 through the Phosphatidylinositol 3-Kinase/AKT Pathway* , 2000, The Journal of Biological Chemistry.

[54]  M. Hallek,et al.  Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. , 2000, Blood.

[55]  Cedric E. Ginestet.  ggplot2: Elegant Graphics for Data Analysis , 2011 .

[56]  S. Perrotta,et al.  p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells. , 2011, Carcinogenesis.

[57]  James M. Roberts,et al.  A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. , 2006, Genes & development.

[58]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.